Recent investigations have focused on the intersection of GLP-1|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GLP agonists are widely employed for addressing type 2 diabetes mellitus, their unexpected impacts on reward circuits, specifically governed by dopaminergic pa